Apoferritin nanoparticle based dual-antigen influenza conjugate vaccine with potential cross-protective efficacy against heterosubtypic influenza virus

In the present work, an apoferritin (AFt) nanoparticle was tested as influenza vaccine carrier by chemically conjugating a matrix protein 2 ectodomain (M2e) antigen peptide or/and the full-length hemagglutinin (HA) antigen on the outer surface of the AFt, with heterobifunctional sSMCC or SM(PEG)24 containing PEG chain as linkers.

To each AFt nanoparticle, about 30-32 M2e or 1.8 HA antigen could be coupled. The AFt-(PEG)24-M2e, in which the M2e was coupled through SM(PEG)24 containing PEG chain, conferred higher protective efficacy in immunized mice than AFt-M2e did, but was less effective than AFt-(PEG)24-HA. When both M2e and HA were coupled, the synthesized dual-antigen vaccine candidate AFt-(PEG)24-M2e/HA elicited high level of M2e and HA antigen-specific antibodies and conferred 100% protection against lethal infection of homologous PR8 H1N1 virus strain and 70% protection against a heterologous A/FM/1/47 (FM1, H1N1) strain, which was more effective than the M2e or HA single antigen vaccine candidates.